NCT04044534

Intranasal Insulin for Posttraumatic Stress Disorder

Intranasal Insulin for Treating Posttraumatic Stress Disorder

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: VA Connecticut Healthcare System · Federal
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To evaluate if intranasal insulin is effective in reducing PTSD symptoms.

Detailed description

The current proposal aims to study the pharmacotherapeutic effects of intranasal insulin on PTSD symptoms and inhibition of amygdala hyperactivation in subjects with PTSD.

Conditions

• PTSD

Interventions

Type	Name	Description
DRUG	Intranasal insulin	Subjects in this arm will receive intranasal insulin (80 IU per day).
DRUG	Placebo	Subjects in this arm will receive placebo.

Timeline

• Start date: 2024-10-31
• Primary completion: 2026-05-31
• Completion: 2026-05-31
• First posted: 2019-08-05
• Last updated: 2025-09-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study